請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71240完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林?輝(Feng-Huei Lin) | |
| dc.contributor.author | Felicia Boendadjaja | en |
| dc.contributor.author | 溫麗潞 | zh_TW |
| dc.date.accessioned | 2021-06-17T05:00:24Z | - |
| dc.date.available | 2023-08-01 | |
| dc.date.copyright | 2018-08-01 | |
| dc.date.issued | 2018 | |
| dc.date.submitted | 2018-07-25 | |
| dc.identifier.citation | 1. Huang, Z.Y. and V.B. Kraus, Does lipopolysaccharide-mediated inflammation have a role in OA? Nature Reviews Rheumatology, 2016. 12(2): p. 123-129.
2. Al-Goblan, A.S., M.A. Al-Alfi, and M.Z. Khan, Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes, 2014. 7: p. 587-91. 3. Neogi, T. and Y.Q. Zhang, Epidemiology of Osteoarthritis. Rheumatic Disease Clinics of North America, 2013. 39(1): p. 1-+. 4. Chen, F.P., C.M. Chang, S.J. Hwang, Y.C. Chen, and F.J. Chen, Chinese herbal prescriptions for osteoarthritis in Taiwan: analysis of national health insurance dataset. Bmc Complementary and Alternative Medicine, 2014. 14. 5. Helmick, C.G., D.T. Felson, R.C. Lawrence, S. Gabriel, R. Hirsch, C.K. Kwoh, M.H. Liang, H.M. Kremers, M.D. Mayes, P.A. Merkel, S.R. Pillemer, J.D. Reveille, J.H. Stone, and N.A.D. Workgrp, Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis and Rheumatism, 2008. 58(1): p. 15-25. 6. Huang, T.L., C.C. Wu, J.S. Yu, S. Sumi, and K.C. Yang, L-Lysine regulates tumor necrosis factor-alpha and matrix metalloproteinase-3 expression in human osteoarthritic chondrocytes. Process Biochemistry, 2016. 51(7): p. 904-911. 7. Mandelbaum, B. and D. Waddell, Etiology and pathophysiology of osteoarthritis. Orthopedics, 2005. 28(2): p. S207-S214. 8. Blagojevic, M., C. Jinks, A. Jeffery, and K.P. Jordan, Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthritis and Cartilage, 2010. 18(1): p. 24-33. 9. Felson, D.T., R.C. Lawrence, P.A. Dieppe, R. Hirsch, C.G. Helmick, J.M. Jordan, R.S. Kington, N.E. Lane, M.C. Nevitt, Y.Q. Zhang, M. Sowers, T. McAlindon, T.D. Spector, A.R. Poole, S.Z. Yanovski, G. Ateshian, L. Sharma, J.A. Buckwalter, K.D. Brandt, and J.F. Fries, Osteoarthritis: New Insights. Part 1: The Disease and Its Risk Factors. Annals of Internal Medicine, 2000. 133(8): p. 635-646. 10. Guilak, F., Biomechanical factors in osteoarthritis. Best Practice & Research in Clinical Rheumatology, 2011. 25(6): p. 815-823. 11. Buckwalter, J.A. and H.J. Mankin, Articular cartilage .1. Tissue design and chondrocyte-matrix interactions. Journal of Bone and Joint Surgery-American Volume, 1997. 79a(4): p. 600-611. 12. Pearle, A.D., R.F. Warren, and S.A. Rodeo, Basic science of articular cartilage and osteoarthritis. Clinics in Sports Medicine, 2005. 24(1): p. 1-+. 13. Buckwalter, J.A. and H.J. Mankin, Articular cartilage .2. Degeneration and osteoarthrosis, repair, regeneration, and transplantation. Journal of Bone and Joint Surgery-American Volume, 1997. 79a(4): p. 612-632. 14. Gentili, C. and R. Cancedda, Cartilage and bone extracellular matrix. Curr Pharm Des, 2009. 15(12): p. 1334-48. 15. Hunter, W., Of the Structure and Disease of Articulating Cartilages (Reprinted from Philos-Trans-R-Soc-Lond, Vol 42, Pg 514-521, 1743). Clinical Orthopaedics and Related Research, 1995(317): p. 3-6. 16. Hunziker, E.B., Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects. Osteoarthritis and Cartilage, 2002. 10(6): p. 432-463. 17. Sandell, L.J., Anabolic factors in degenerative joint disease. Current Drug Targets, 2007. 8(2): p. 359-365. 18. Takahashi, N., K. Rieneck, P.M. van der Kraan, H.M. van Beuningen, E.L. Vitters, K. Bendtzen, and W.B. van den Berg, Elucidation of IL-1/TGF-beta interactions in mouse chondrocyte cell line by genome-wide gene expression. Osteoarthritis and Cartilage, 2005. 13(5): p. 426-438. 19. Scharstuhl, A., H.L. Glansbeek, H.M. van Beuningen, E.L. Vitters, P.M. van der Kraan, and W.B. van den Berg, Inhibition of endogenous TGF-beta during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. Journal of Immunology, 2002. 169(1): p. 507-514. 20. Moulharat, N., C. Lesur, M. Thomas, G. Rolland-Valognes, P. Pastoureau, P. Anract, F. De Ceuninck, and M. Sabatini, Effects of transforming growth factor-beta on aggrecanase production and proteoglycan degradation by human chondrocytes in vitro. Osteoarthritis and Cartilage, 2004. 12(4): p. 296-305. 21. Pelletier, J.P., J. Martel-Pelletier, and S.B. Abramson, Osteoarthritis, an inflammatory disease - Potential implication for the selection of new therapeutic targets. Arthritis and Rheumatism, 2001. 44(6): p. 1237-1247. 22. Wieland, H.A., M. Michaelis, B.J. Kirschbaum, and K.A. Rudolphi, Osteoarthritis - An untreatable disease? Nature Reviews Drug Discovery, 2005. 4(4): p. 331-344. 23. Li, Y. and L. Xu, Advances in understanding cartilage remodeling. F1000Res, 2015. 4(F1000 Faculty Rev): p. 642. 24. Kim, H., D. Kang, Y. Cho, and J.H. Kim, Epigenetic Regulation of Chondrocyte Catabolism and Anabolism in Osteoarthritis. Molecules and Cells, 2015. 38(8): p. 677-684. 25. Kapoor, M., J. Martel-Pelletier, D. Lajeunesse, J.P. Pelletier, and H. Fahmi, Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nature Reviews Rheumatology, 2011. 7(1): p. 33-42. 26. Coluet, J., C. Vinatier, C. Merceron, M. Pot-vaucel, Y. Maugars, P. Weiss, G. Grimandi, and J. Guicheux, From osteoarthritis treatments to future regenerative therapies for cartilage. Drug Discovery Today, 2009. 14(19-20): p. 913-925. 27. Calamia, V., J. Mateos, P. Fernandez-Puente, L. Lourido, B. Rocha, C. Fernandez-Costa, E. Montell, J. Verges, C. Ruiz-Romero, and F.J. Blanco, A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine. Sci Rep, 2014. 4: p. 5069. 28. Natoli, R.M. and K.A. Athanasiou, Traumatic loading of articular cartilage: Mechanical and biological responses and post-injury treatment. Biorheology, 2009. 46(6): p. 451-485. 29. Sellam, J. and F. Berenbaum, [Osteoarthritis and obesity]. Rev Prat, 2012. 62(5): p. 621-4. 30. Aigner, T., S. Soeder, and J. Haag, Il-1 beta and BMPS - Interactive players of cartilage matrix degradation and regeneration. European Cells & Materials, 2006. 12: p. 49-56. 31. Tan, L.J., H.B. Peng, M. Osaki, B.K. Choy, P.E. Auron, L.J. Sandell, and M.B. Goldring, Egr-1 mediates transcriptional repression of COL2A1 promoter activity by interleukin-1 beta. Journal of Biological Chemistry, 2003. 278(20): p. 17688-17700. 32. Zhang, W., H. Ouyang, C.R. Dass, and J. Xu, Current research on pharmacologic and regenerative therapies for osteoarthritis. Bone Res, 2016. 4: p. 15040. 33. Bonnington, K.E. and M.J. Kuehn, Protein selection and export via outer membrane vesicles. Biochimica Et Biophysica Acta-Molecular Cell Research, 2014. 1843(8): p. 1612-1619. 34. Yoshino, S., E. Sasatomi, and M. Ohsawa, Bacterial lipopolysaccharide acts as an adjuvant to induce autoimmune arthritisin mice. Immunology, 2000. 99(4): p. 607-614. 35. Lorenz, W., C. Buhrmann, A. Mobasheri, C. Lueders, and M. Shakibaei, Bacterial lipopolysaccharides form procollag-enendotoxin complexes that trigger cartilage inflammation and degeneration: implications for the development of rheumatoid arthritis. Arthritis Research & Therapy, 2013. 15(5). 36. Jordan, K.M., N.K. Arden, M. Doherty, B. Bannwarth, J.W.J. Bijlsma, P. Dieppe, K. Gunther, H. Hauselmann, G. Herrero-Beaumont, P. Kaklamanis, S. Lohmander, B. Leeb, M. Lequesne, B. Mazieres, E. Martin-Mola, K. Pavelka, A. Pendleton, L. Punzi, U. Serni, B. Swoboda, G. Verbruggen, I. Zimmerman-Gorska, and M. Dougados, EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Annals of the Rheumatic Diseases, 2003. 62(12): p. 1145-1155. 37. Hochberg, M.C., R.D. Altman, K.T. April, M. Benkhalti, G. Guyatt, J. McGowan, T. Towheed, V. Welch, G. Wells, and P. Tugwell, American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care & Research, 2012. 64(4): p. 465-474. 38. Zhang, W., R.W. Moskowitz, G. Nuki, S. Abramson, R.D. Altman, N. Arden, S. Bierma-Zeinstra, K.D. Brandt, P. Croft, M. Doherty, M. Dougados, M. Hochberg, D.J. Hunter, K. Kwoh, L.S. Lohmander, and P. Tugwell, OARSI recommendations for the management of hip and knee osteoarthritis, Part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis and Cartilage, 2007. 15(9): p. 981-1000. 39. Zhang, W., R.W. Moskowitz, G. Nuki, S. Abramson, R.D. Altman, N. Arden, S. Bierma-Zeinstra, K.D. Brandt, P. Croft, M. Doherty, M. Dougados, M. Hochberg, D.J. Hunter, K. Kwoh, L.S. Lohmander, and P. Tugwell, OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage, 2008. 16(2): p. 137-162. 40. Zhang, W., G. Nuki, R.W. Moskowitz, S. Abramson, R.D. Altman, N.K. Arden, S. Bierma-Zeinstra, K.D. Brandt, P. Croft, M. Doherty, M. Dougados, M. Hochberg, D.J. Hunter, K. Kwoh, L.S. Lohmander, and P. Tugwell, OARSI recommendations for the management of hip and knee osteoarthritis Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis and Cartilage, 2010. 18(4): p. 476-499. 41. Fang, H.W., Trends and Challenges of Cartilage Tissue Engineering. Biomedical Engineering-Applications Basis Communications, 2009. 21(3): p. 149-155. 42. Mason, C. and P. Dunnill, A brief definition of regenerative medicine. Regenerative Medicine, 2008. 3(1): p. 1-5. 43. Runhaar, J., M. van Middelkoop, M. Reijman, S. Willemsen, E.H. Oei, D. Vroegindeweij, G. van Osch, B. Koes, and S.M.A. Bierma-Zeinstra, Prevention of Knee Osteoarthritis in Overweight Females: The First Preventive Randomized Controlled Trial in Osteoarthritis. American Journal of Medicine, 2015. 128(8): p. 888-+. 44. Zhang, W., A. Jones, and M. Doherty, Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomised controlled trials. Annals of the Rheumatic Diseases, 2004. 63(8): p. 901-907. 45. Furst, D.E., Are There Differences among Nonsteroidal Antiinflammatory Drugs - Comparing Acetylated Salicylates, Nonacetylated Salicylates, and Nonacetylated Nonsteroidal Antiinflammatory Drugs. Arthritis and Rheumatism, 1994. 37(1): p. 1-9. 46. Cannon, G.W., J.R. Caldwell, P. Holt, B. McLean, B. Seidenberg, J. Bolognese, E. Ehrich, S. Mukhopadhyay, B. Daniels, and R.P.I.P. Study, Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium - Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis and Rheumatism, 2000. 43(5): p. 978-987. 47. US Food and Drug Administration. FDA Limits Acetaminophen in Prescription Combination Products; Requires Liver Toxicity Warnings. Silver Spring: FDA, 2011. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm239894.htm. 48. Jevsevar, D.S., Treatment of Osteoarthritis of the Knee: Evidence-Based Guideline, 2nd Edition. Journal of the American Academy of Orthopaedic Surgeons, 2013. 21(9): p. 571-576. 49. Towheed, T.E., L. Maxwell, M.G. Judd, M. Catton, M.C. Hochberg, and G. Wells, Acetaminophen for osteoarthritis. Cochrane Database of Systematic Reviews, 2006(1). 50. Pirmohamed, M., S. James, S. Meakin, C. Green, A.K. Scott, T.J. Walley, K. Farrar, B.K. Park, and A.M. Breckenridge, Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. British Medical Journal, 2004. 329(7456): p. 15-19. 51. Rodriguez, L.A.G. and H. Jick, Risk of Upper Gastrointestinal-Bleeding and Perforation Associated with Individual Nonsteroidal Antiinflammatory Drugs. Lancet, 1994. 343(8900): p. 769-772. 52. Langman, M.J.S., J. Weil, P. Wainwright, D.H. Lawson, M.D. Rawlins, R.F.A. Logan, M. Murphy, M.P. Vessey, and D.G. Colinjones, Risks of Bleeding Peptic-Ulcer Associated with Individual Nonsteroidal Antiinflammatory Drugs. Lancet, 1994. 343(8905): p. 1075-1078. 53. US Food and Drug Administration Information for Healthcare Professionals: Celecoxib (marketed as Celebrex). Silver Spring: FDA, 2005. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124655.htm. 54. US Food and Drug Administration. FDA Public Health Advisory: Safety of Vioxx. Silver Spring: FDA, 2004. Available at http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm106274.htm. 55. US Food and Drug Administration. Information for Healthcare Professionals: Valdecoxib (marketed as Bextra). Silver Spring: FDA, 2005. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124649.htm. 56. Brown, G.A., AAOS Clinical Practice Guideline: Treatment of Osteoarthritis of the Knee: Evidence-Based Guideline, 2nd Edition. Journal of the American Academy of Orthopaedic Surgeons, 2013. 21(9): p. 577-579. 57. Balazs, E.A. and J.L. Denlinger, Viscosupplementation - a New Concept in the Treatment of Osteoarthritis. Journal of Rheumatology, 1993. 20: p. 3-9. 58. Moreland, L.W., Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Research & Therapy, 2003. 5(2): p. 54-67. 59. Peyron, J.G., Intraarticular Hyaluronan Injections in the Treatment of Osteoarthritis - State-of-the-Art Review. Journal of Rheumatology, 1993. 20: p. 10-15. 60. Bradamante, S., L. Barenghi, and A. Villa, Cardiovascular protective effects of resveratrol. Cardiovascular Drug Reviews, 2004. 22(3): p. 169-188. 61. Delmas, D., A. Lancon, D. Colin, B. Jannin, and N. Latruffe, Resveratrol as a chemopreventive agent: A promising molecule for fighting cancer. Current Drug Targets, 2006. 7(4): p. 423-442. 62. Fulda, S. and K.M. Debatin, Resveratrol modulation of signal transduction in apoptosis and cell survival: A mini-review. Cancer Detection and Prevention, 2006. 30(3): p. 217-223. 63. Csaki, C., N. Keshishzadeh, K. Fischer, and M. Shakibaei, Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochemical Pharmacology, 2008. 75(3): p. 677-687. 64. Dave, M., M. Attur, G. Palmer, H.E. Al-Mussawir, L. Kennish, J. Patel, and S.B. Abramson, The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP production. Arthritis and Rheumatism, 2008. 58(9): p. 2786-2797. 65. Smoliga, J.M. and O. Blanchard, Enhancing the Delivery of Resveratrol in Humans: If Low Bioavailability is the Problem, What is the Solution? Molecules, 2014. 19(11): p. 17154-17172. 66. Camont, L., C.H. Cottart, Y. Rhayem, V. Nivet-Antoine, R. Djelidi, F. Collin, J.L. Beaudeux, and D. Bonnefont-Rousselot, Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions. Analytica Chimica Acta, 2009. 634(1): p. 121-128. 67. Zong, A.Z., H.Z. Cao, and F.S. Wang, Anticancer polysaccharides from natural resources: A review of recent research. Carbohydrate Polymers, 2012. 90(4): p. 1395-1410. 68. Kozarski, M., A. Klaus, M. Niksic, M.M. Vrvic, N. Todorovic, D. Jakovljevic, and L.J.L.D. Van Griensven, Antioxidative activities and chemical characterization of polysaccharide extracts from the widely used mushrooms Ganoderma applanatum, Ganoderma lucidum, Lentinus edodes and Trametes versicolor. Journal of Food Composition and Analysis, 2012. 26(1-2): p. 144-153. 69. Kang, M.C., S.Y. Kim, Y.T. Min, E.A. Kim, S.H. Lee, S.C. Ko, W.A.J.P. Wijesinghe, K.W. Samarakoon, Y.S. Kim, J.H. Cho, H.S. Jang, and Y.J. Jeon, In vitro and in vivo antioxidant activities of polysaccharide purified from aloe vera (Aloe barbadensis) gel. Carbohydrate Polymers, 2014. 99: p. 365-371. 70. Suvakanta, D., M.P. Narsimha, D. Pulak, C. Joshabir, and D. Biswajit, Optimization and characterization of purified polysaccharide from Musa sapientum L. as a pharmaceutical excipient. Food Chemistry, 2014. 149: p. 76-83. 71. Kaderli, S., C. Boulocher, E. Pillet, D. Watrelot-Virieux, A.L. Rougemont, T. Roger, E. Viguier, R. Gurny, L. Scapozza, and O. Jordan, A novel biocompatible hyaluronic acid-chitosan hybrid hydrogel for osteoarthrosis therapy. International Journal of Pharmaceutics, 2015. 483(1-2): p. 158-168. 72. Han, G.Y., Q.X. Chen, F. Liu, Z. Cui, H.R. Shao, F.Y. Liu, A.B. Ma, J.S. Liao, B. Guo, Y.W. Guo, F.S. Wang, P.X. Ling, and X.F. Mei, Low molecular weight xanthan gum for treating osteoarthritis. Carbohydrate Polymers, 2017. 164: p. 386-395. 73. Lu, H.D., H.Q. Zhao, K. Wang, and L.L. Lv, Novel hyaluronic acid-chitosan nanoparticles as non-viral gene delivery vectors targeting osteoarthritis. International Journal of Pharmaceutics, 2011. 420(2): p. 358-365. 74. Chen, Q.X., X.T. Shao, P.X. Ling, F. Liu, H.R. Shao, A.B. Ma, J.X. Wu, W. Zhang, F.Y. Liu, G.Y. Han, and F.S. Wang, Low molecular weight xanthan gum suppresses oxidative stress-induced apoptosis in rabbit chondrocytes. Carbohydrate Polymers, 2017. 169: p. 255-263. 75. Puperi, D.S., R.W. O'Connell, Z.E. Punske, Y. Wu, J.L. West, and K.J. Grande-Allen, Hyaluronan Hydrogels for a Biomimetic Spongiosa Layer of Tissue Engineered Heart Valve Scaffolds. Biomacromolecules, 2016. 17(5): p. 1766-1775. 76. Xing, D., B. Wang, Q. Liu, Y. Ke, Y.K. Xu, Z.C. Li, and J.H. Lin, Intra-articular Hyaluronic Acid in Treating Knee Osteoarthritis: a PRISMA-Compliant Systematic Review of Overlapping Meta-analysis. Scientific Reports, 2016. 6. 77. Mooibroek, T.J., J.M. Casas-Solvas, R.L. Harniman, C. Renney, T.S. Carter, M.P. Crump, and A.P. Davis, A threading receptor for polysaccharides. Nature Chemistry, 2016. 8(1): p. 69-74. 78. Knudson, C.B. and W. Knudson, Hyaluronan and CD44 - Modulators of chondrocyte metabolism. Clinical Orthopaedics and Related Research, 2004(427): p. S152-S162. 79. Ravanetti, F., C. Galli, E. Manfredi, A.M. Cantoni, E. Scarpa, G.M. Macaluso, and A. Cacchioli, Chitosan-based scaffold modified with D-(+) raffinose for cartilage repair: an in vivo study. Journal of Negative Results in Biomedicine, 2015. 14. 80. Kumar, R.A., A. Sivashanmugam, S. Deepthi, S. Iseki, K.P. Chennazhi, S.V. Nair, and R. Jayakumar, Injectable Chitin-Poly(epsilon-caprolactone)/Nanohydroxyapatite Composite Microgels Prepared by Simple Regeneration Technique for Bone Tissue Engineering. Acs Applied Materials & Interfaces, 2015. 7(18): p. 9399-9409. 81. Henrotin, Y., R. Raman, P. Richette, H. Bard, J. Jerosch, T. Conrozier, X. Chevalier, and A. Migliore, Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. Seminars in Arthritis and Rheumatism, 2015. 45(2): p. 140-149. 82. Shao, H.R., Y. Jin, G.Y. Han, P. Jiang, X.Q. Zhu, F. Liu, Z.G. Son, M. Li, and P.X. Ling, Viscosupplementation of synovial fluid with xanthan gum for treatment of osteoarthritis and its clearance kinetics in the rabbit knee joint. Biorheology, 2014. 51(4-5): p. 305-314. 83. Chen, Q.X., X.T. Shao, P.X. Ling, F. Liu, G.Y. Han, and F.S. Wang, Recent advances in polysaccharides for osteoarthritis therapy. European Journal of Medicinal Chemistry, 2017. 139: p. 926-935. 84. Peng, Q., M. Li, F. Xue, and H.J. Liu, Structure and immunobiological activity of a new polysaccharide from Bletilla striata. Carbohydrate Polymers, 2014. 107: p. 119-123. 85. Wang, Y., D. Liu, S.J. Chen, Y. Wang, H.X. Jiang, and H.P. Yin, A new glucomannan from Bletilla striata: Structural and anti-fibrosis effects. Fitoterapia, 2014. 92: p. 72-78. 86. Wang, C.M., J.T. Sun, Y. Luo, W.H. Xue, H.J. Diao, L. Dong, J.N. Chen, and J.F. Zhang, A polysaccharide isolated from the medicinal herb Bletilla striata induces endothelial cells proliferation and vascular endothelial growth factor expression in vitro. Biotechnology Letters, 2006. 28(8): p. 539-543. 87. Wu, X.G., X. Yang, H.R. Jiang, Y.Y. Xu, T. Liu, X.J. Zang, and H.Q. Gong, Safety Evaluation of Intracameral and Subconjunctival Injection of a Novel Mucoadhesive Polysaccharide Isolated from Bletilla striata in Rabbit Eye. Journal of Ocular Pharmacology and Therapeutics, 2012. 28(4): p. 369-380. 88. Liu, J.Y., H.C. Wang, Y. Yin, N. Li, P.L. Cai, and S.L. Yang, Controlled acetylation of water-soluble glucomannan from Bletilla striata. Carbohydrate Polymers, 2012. 89(1): p. 158-162. 89. Zhang, Y.S., T. Lv, M. Li, T. Xue, H. Liu, W.M. Zhang, X.Y. Ding, and Z.H. Zhuang, Anti-aging effect of polysaccharide from Bletilla striate on nematode Caenorhabditis elegans. Pharmacognosy Magazine, 2015. 11(43): p. 449-454. 90. Luo, Y., H.J. Diao, S.H. Xia, L. Dong, J.N. Chen, and J.F. Zhang, A physiologically active polysaccharide hydrogel promotes wound healing. Journal of Biomedical Materials Research Part A, 2010. 94a(1): p. 193-204. 91. Xiang, Y.L., Q. Ye, W.B. Li, W.L. Xu, and H.J. Yang, Preparation of wet-spun polysaccharide fibers from Chinese medicinal Bletilla striata. Materials Letters, 2014. 117: p. 208-210. 92. Lai, Y.L., Y.Y. Lin, S. Sadhasivam, C.Y. Kuan, C.Y. Chi, G.C. Dong, and F.H. Lin, Efficacy of Bletilla striata polysaccharide on hydrogen peroxide-induced apoptosis of osteoarthritic chondrocytes. Journal of Polymer Research, 2018. 25(2). 93. Chen, M.P., S.H. Yang, C.H. Chou, K.C. Yang, C.C. Wu, Y.H. Cheng, and F.H. Lin, The chondroprotective effects of ferulic acid on hydrogen peroxide-stimulated chondrocytes: inhibition of hydrogen peroxide-induced pro-inflammatory cytokines and metalloproteinase gene expression at the mRNA level. Inflammation Research, 2010. 59(8): p. 587-595. 94. Yu, F.Y., S.B. Lu, X.M. Cui, B. Zhao, W.J. Xu, M. Yuan, M.X. Sun, W.T. Zhang, and J.X. Huang, [Biological characterization of rabbit's articular chondrocytes by confluent culture in vitro]. Zhonghua Wai Ke Za Zhi, 2006. 44(12): p. 848-51. 95. Kim, K.M., S.B. Lee, S.H. Lee, Y.K. Lee, and K.N. Kim, Comparison of validity between WST-1 and MTT test in bioceramic materials. Bioceramics, Vol 17, 2005. 284-286: p. 585-588. 96. Lo, W.C., W.H. Chen, T.C. Lin, S.M. Hwang, R. Zeng, W.C. Hsu, Y.M. Chiang, M.C. Liu, D.F. Williams, and W.P. Deng, Preferential therapy for osteoarthritis by cord blood MSCs through regulation of chondrogenic cytokines. Biomaterials, 2013. 34(20): p. 4739-4748. 97. Bhosale, A.M. and J.B. Richardson, Articular cartilage: structure, injuries and review of management. British Medical Bulletin, 2008. 87(1): p. 77-95. 98. Wang, S.N., G.P. Xie, C.H. Qin, Y.R. Chen, K.R. Zhang, X. Li, Q. Wu, W.Q. Dong, J. Yang, and B. Yu, Aucubin prevents interleukin-1 beta induced inflammation and cartilage matrix degradation via inhibition of NF-kappaB signaling pathway in rat articular chondrocytes. Int Immunopharmacol, 2015. 24(2): p. 408-415. 99. Neely, W.B., Infrared Spectra of Carbohydrates. Advances in Carbohydrate Chemistry, 1957. 12: p. 13-33. 100. Melchiorri, C., R. Meliconi, L. Frizziero, T. Silvestri, L. Pulsatelli, I. Mazzetti, R.M. Borzi, M. Uguccioni, and A. Facchini, Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis and Rheumatism, 1998. 41(12): p. 2165-2174. 101. Henderson, B. and E.R. Pettipher, Arthritogenic Actions of Recombinant Il-1 and Tumor Necrosis Factor-Alpha in the Rabbit - Evidence for Synergistic Interactions between Cytokines Invivo. Clinical and Experimental Immunology, 1989. 75(2): p. 306-310. 102. Marcu, K.B., M. Otero, E. Olivotto, R.M. Borzi, and M.B. Goldring, NF-kappa B Signaling: Multiple Angles to Target OA. Current Drug Targets, 2010. 11(5): p. 599-613. 103. Vincenti, M.P. and C.E. Brinckerhoff, Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Research, 2002. 4(3): p. 157-164. 104. Lopez-Armada, M.J., B. Carames, M. Lires-Dean, B. Cillero-Pastor, C. Ruiz-Romero, F. Galdo, and F.J. Blanco, Cytokines, tumor necrosis factor-alpha and interleukin-1beta, differentially regulate apoptosis in osteoarthritis cultured human chondrocytes. Osteoarthritis Cartilage, 2006. 14(7): p. 660-9. 105. Wang, P., P.P. Guan, C. Guo, F. Zhu, K. Konstantopoulos, and Z.Y. Wang, Fluid shear stress-induced osteoarthritis: roles of cyclooxygenase-2 and its metabolic products in inducing the expression of proinflammatory cytokines and matrix metalloproteinases. Faseb Journal, 2013. 27(12): p. 4664-4677. 106. Zanotti, S. and E. Canalis, Interleukin 6 mediates selected effects of Notch in chondrocytes. Osteoarthritis and Cartilage, 2013. 21(11): p. 1766-1773. 107. Ashraf, S., P.I. Mapp, J. Burston, A.J. Bennett, V. Chapman, and D.A. Walsh, Augmented pain behavioural responses to intra-articular injection of nerve growth factor in two animal models of osteoarthritis. Annals of the Rheumatic Diseases, 2014. 73(9): p. 1710-1718. 108. Enochson, L., J. Stenberg, M. Brittberg, and A. Lindahl, GDF5 reduces MMP13 expression in human chondrocytes via DKK1 mediated canonical Wnt signaling inhibition. Osteoarthritis and Cartilage, 2014. 22(4): p. 566-577. 109. Halbwirth, F., E. Niculescu-Morzsa, H. Zwickl, C. Bauer, and S. Nehrer, Mechanostimulation changes the catabolic phenotype of human dedifferentiated osteoarthritic chondrocytes. Knee Surgery Sports Traumatology Arthroscopy, 2015. 23(1): p. 104-111. 110. Fernandes, J.C., J. Martel-Pelletier, and J.P. Pelletier, The role of cytokines in osteoarthritis pathophysiology. Biorheology, 2002. 39(1-2): p. 237-46. 111. van Beuningen, H.M., P.M. van der Kraan, O.J. Arntz, and W.B. van den Berg, Transforming growth factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. Lab Invest, 1994. 71(2): p. 279-90. 112. Hui, W., A.D. Rowan, and T. Cawston, Modulation of the expression of matrix metalloproteinase and tissue inhibitors of metalloproteinases by TGF-beta1 and IGF-1 in primary human articular and bovine nasal chondrocytes stimulated with TNF-alpha. Cytokine, 2001. 16(1): p. 31-5. 113. Brew, C.J., P.D. Clegg, R.P. Boot-Handford, J.G. Andrew, and T. Hardingham, Gene expression in human chondrocytes in late osteoarthritis is changed in both fibrillated and intact cartilage without evidence of generalised chondrocyte hypertrophy. Ann Rheum Dis, 2010. 69(1): p. 234-40. 114. Fukui, N., Y. Ikeda, T. Ohnuki, N. Tanaka, A. Hikita, H. Mitomi, T. Mori, T. Juji, Y. Katsuragawa, S. Yamamoto, M. Sawabe, S. Yamane, R. Suzuki, L.J. Sandell, and T. Ochi, Regional differences in chondrocyte metabolism in osteoarthritis: a detailed analysis by laser capture microdissection. Arthritis Rheum, 2008. 58(1): p. 154-63. 115. Young, I.C., S.T. Chuang, C.H. Hsu, Y.J. Sun, H.C. Liu, Y.S. Chen, and F.H. Lin, Protective effects of aucubin on osteoarthritic chondrocyte model induced by hydrogen peroxide and mechanical stimulus. BMC Complement Altern Med, 2017. 17(1): p. 91. 116. Chen, W.C., Y.H. Wei, J.B. Huang, I.M. Chu, and C.L. Yao, Biological Effects of Oligosaccharide Chondroitin Sulfate C on Human Articular Chondrocytes. Biomedical Engineering-Applications Basis Communications, 2011. 23(3): p. 245-252. 117. Clouet, J., C. Vinatier, C. Merceron, M. Pot-vaucel, Y. Maugars, P. Weiss, G. Grimandi, and J. Guicheux, From osteoarthritis treatments to future regenerative therapies for cartilage. Drug Discov Today, 2009. 14(19-20): p. 913-25. 118. Chang, C.H., Y.M. Hsu, Y.C. Chen, F.H. Lin, S. Sadhasivam, S.T. Loo, and S. Savitha, Anti-inflammatory effects of hydrophilic and lipophilic statins with hyaluronic acid against LPS-induced inflammation in porcine articular chondrocytes. J Orthop Res, 2014. 32(4): p. 557-65. 119. Im, H.J., X. Li, D. Chen, D. Yan, J. Kim, M.B. Ellman, G.S. Stein, B. Cole, R. Kc, G. Cs-Szabo, and A.J. van Wijnen, Biological effects of the plant-derived polyphenol resveratrol in human articular cartilage and chondrosarcoma cells. J Cell Physiol, 2012. 227(10): p. 3488-97. 120. Juhasz, T., C. Matta, C. Somogyi, E. Katona, R. Takacs, R.F. Soha, I.A. Szabo, C. Cserhati, R. Szody, Z. Karacsonyi, E. Bako, P. Gergely, and R. Zakany, Mechanical loading stimulates chondrogenesis via the PKA/CREB-Sox9 and PP2A pathways in chicken micromass cultures. Cell Signal, 2014. 26(3): p. 468-82. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71240 | - |
| dc.description.abstract | 退化性關節炎(Osteoarthritis，OA)是一種慢性關節損傷疾病，其漸進性的病程會導致軟骨纖維化或缺損，且軟骨組織受損後不易復原。對於退化性關節炎，當今醫療只能針對症狀進行緩解而無法預防或治癒該疾病，因此退化性關節炎在再生醫學研究方向為持續發展新的治療策略與生醫材料。已有文獻指出白藜蘆醇(Resveratrol) 能顯著抑制退化性關節炎產生之發炎狀態，但白藜蘆醇在進入臨床試驗後其生物藥效率並未達到共識，為了改善此點，本實驗目的為利用傳統中藥白芨多醣體(Polysaccharide Isolated from Bletilla striata)的抗氧化、抗發炎以及促進受損組織細胞修復的功能來加強白藜蘆醇減緩軟骨細胞之發炎情況。
在本研究中，將50 µM白藜蘆醇混合100 µg/ml白芨多醣體的混合物(RB)作用於受脂多醣誘導發炎的豬軟骨細胞實驗模型中，評估RB對細胞之細胞毒性、細胞外基質活性與基因表現。實驗結果顯示萃取之白芨多醣體具有正確之官能基，且RB經由WST-1試驗和 LIVE/DEAD 染色分析證實具有良好生物相容性。RB經由ICC檢測第二型膠原蛋白含量與Alcian blue染色結果顯示能維持細胞外基質的表現量，RB也能有效降低脂多醣刺激軟骨所造成的發炎基因表現量。綜合上述實驗結果白芨多醣體能維持細胞外基質的表現量，白藜蘆醇則能減輕發炎症狀，而白芨多醣體與白藜蘆醇之混合物能維持兩者之優點，因此在早期治療及預防退化性關節炎之症狀具有很大的潛力。 | zh_TW |
| dc.description.abstract | Osteoarthritis (OA) is a chronic joint injury disease. Its progressive course leads to cartilage fibrosis due to tissue nature to not easy to recover after damage. Present aids for OA are primarily focuses for alleviating the symptoms of the disease rather than prevent or cure the disease process. Therefore, development of new therapeutic strategies and biomaterials are always on-demand for OA regenerative medicine. It has been reported that resveratrol can inhibit the inflammatory rate of OA, but bioavailability of resveratrol is still controversy. In order to improve this point, the polysaccharide isolated from Bletilla striata (BSP) is added. Recent studies found that BSP has antioxidative and anti-inflammatory properties, which can strengthen the role of resveratrol to provide an anti-inflammatory effect.
In this study, a mixture of 50 μM resveratrol and 100 µg/mL BSP (RB) was tested for cytotoxicity potential, then applied to an experimental model of OA-like chondrocytes induced by lipopolysaccharide (LPS) thus evaluated its ECM activity and gene expression. The experimental results showed that the BSP have the correct functional groups, and RB has been proved to have good biocompatibility through the WST-1 test and LIVE/DEAD staining. ICC type II collagen, Alcian blue staining, and gene expression evaluation showed that RB able to maintained the expression of ECM and inflammatory-related genes caused by LPS-stimulated chondrocyte, could be effectively reduced. To conclude, BSP can significantly maintain the expression of extracellular matrix, while resveratrol can reduce the symptoms of inflammation, and the mixture of BSP and resveratrol has the advantages of both, so it has great potentials for OA early treatment and prevention. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T05:00:24Z (GMT). No. of bitstreams: 1 ntu-107-R05548059-1.pdf: 3683618 bytes, checksum: 75dd30c59afb24afe1bc912056a4b298 (MD5) Previous issue date: 2018 | en |
| dc.description.tableofcontents | 口試委員會審定書 #
ACKNOWLEDGEMENTS i 中文摘要 ii ABSTRACT iii TABLE OF CONTENTS iv LIST OF FIGURES vii LIST OF TABLES ix Abbrevations LISt x Chapter 1 Introduction 1 1.1 Osteoarthritis…………. 1 1.1.1 Cartilage 2 1.1.2 Metabolism of Chondrocyte 4 1.1.3 Pathogenesis and Inflammation of Osteoarthritis 5 1.2 Lipopolysaccharide Induced Model of Osteoarthritis 6 1.3 Current Preventions and Treatments 8 1.3.1 Pharmacologic Therapies 8 1.3.2 Intra-articular Injection 10 1.4 Resveratrol 10 1.5 Polysaccharide for OA 11 1.5.1 Polysaccharide Extracted from Bletilla striata (BSP) 13 1.5.2 BSP-based Biomaterials 14 1.6 Purpose of Study 14 Chapter 2 Materials and Methods 15 2.1 Experiment Design 15 2.2 List of Materials and Devices 16 2.2.1 Reagents 16 2.2.2 Equipment 17 2.3 Extraction of Polysaccharide from Bletilla striata 18 2.4 Porcine Primary Chondrocyte Cell culture 19 2.4.1 Isolation of Porcine Chondrocyte 19 2.4.2 Porcine Chondrocyte Culture 19 2.5 Cell Viability of BSP and Resveratrol 20 2.5.1 L929 Cell Line Culture 20 2.5.2 WST-1 Cell Viability Assay 20 2.5.3 LIVE/DEAD Staining 21 2.6 Osteoarthritis Like Chondrocyte 22 2.6.1 Therapy group 23 2.6.2 Prevention group 23 2.7 Protective Efficiency of BSP Mixed with Resveratrol Against OA-like Chondrocyte 23 2.7.1 RNA Extraction and Gene Expression of Chondrocytes 23 2.7.2 Alcian Blue Staining 24 2.7.3 Immunocytochemistry Staining 25 2.8 Statistical Analysis 26 Chapter 3 Results and Discussion 27 3.1 Extraction of BSP 27 3.2 Structural Analyses of BSP 27 3.2.1 Functional Groups Analysis by Fourier Transform Infrared Spectroscopy 27 3.2.2 Nuclear Magnetic Resonance Spectroscopy Analysis 28 3.3 The Evaluation of Viability 32 3.3.1 WST-1 Cell Viability Assay 32 3.3.2 LIVE/DEAD Staining 33 3.4 Efficiency of BSP Mixed with Resveratrol Against OA-like Chondrocyte for Therapy Group 35 3.4.1 Gene Expression Evaluation of Therapy Group 35 3.4.2 Alcian Blue Staining of Therapy Group 38 3.4.3 Immunocytochemistry Staining of Therapy Group 40 3.5 Protective Efficiency of BSP Mixed with Resveratrol Against OA-like Chondrocyte for Prevention Group 42 3.5.1 Gene Expression Evaluation of Prevention Group 42 3.5.2 Alcian Blue Staining of Prevention Group 44 3.5.3 Immunocytochemistry Staining of Prevention Group 46 Chapter 4 Conclusion 49 Chapter 5 Perspective and Future Studies 51 References 52 | |
| dc.language.iso | en | |
| dc.subject | 氧化壓力 | zh_TW |
| dc.subject | 退化性關節炎 | zh_TW |
| dc.subject | 軟骨細胞 | zh_TW |
| dc.subject | 白藜蘆醇 | zh_TW |
| dc.subject | 白芨 | zh_TW |
| dc.subject | osteoarthritis | en |
| dc.subject | oxidative stress | en |
| dc.subject | Bletilla striata | en |
| dc.subject | resveratrol | en |
| dc.subject | chondrocytes | en |
| dc.title | 白芨多醣體與白藜蘆醇應用於預防及早期治療退化性關節炎 | zh_TW |
| dc.title | The Evaluation of Polysaccharide from Bletilla Striata Mixed with Resveratrol for Osteoarthritis Prevention in Early Phase | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 106-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 陳克紹(Ko-Shao Chen),孫瑞昇(Jui-Sheng Sun),柯承志(Cherng-Jyh Ke) | |
| dc.subject.keyword | 退化性關節炎,氧化壓力,白芨,白藜蘆醇,軟骨細胞, | zh_TW |
| dc.subject.keyword | osteoarthritis,oxidative stress,Bletilla striata,resveratrol,chondrocytes, | en |
| dc.relation.page | 60 | |
| dc.identifier.doi | 10.6342/NTU201801946 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2018-07-26 | |
| dc.contributor.author-college | 工學院 | zh_TW |
| dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
| 顯示於系所單位： | 醫學工程學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-107-1.pdf 未授權公開取用 | 3.6 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。